WuXi Biologics Showcases Strong Financial Performance in 2025 Interim Results
WuXi Biologics Reports Strong Financial Performance in 2025 Interim Results
WuXi Biologics (Cayman) Inc., under the stock code 2269.HK, has released its interim financial results for the first half of 2025, showing remarkable growth across multiple financial metrics. The company, a leading global provider of Contract Research, Development, and Manufacturing Organization (CRDMO) services, indicated a revenue increase of 16.1% year-over-year, totaling RMB 9,953.2 million. Notably, revenue growth from continuing operations surged by 20.2%.
Financial Highlights
The report outlines substantial gains in gross profit, with a Year-over-Year (YoY) increase of 27.0% reaching RMB 4,252.9 million, and the gross profit margin heightened to 42.7%, up by 3.6% YoY. These figures underscore the effectiveness of WuXi Biologics' operational strategies, notably the
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.